Suppr超能文献

组胺(H1)拮抗剂与豚鼠气道高反应性

Histamine(H1) antagonists and airway hyperreactivity in the guinea-pig.

作者信息

Hoshiko K, Chapman I D, Morley J

机构信息

Preclinical Research, Sandoz Pharma Ltd., Basel, Switzerland.

出版信息

Agents Actions Suppl. 1991;34:323-33.

PMID:1686527
Abstract

Ketotifen inhibits development of airway hyperreactivity in guinea-pigs exposed to PAF, (+/-)isoprenaline, immune complexes or endotoxin. Ketotifen is not a competitive histamine(H1) antagonist, so that it cannot be concluded that there is mandatory involvement of histamine in the development or expression of these forms of airway hyperreactivity. This conclusion has been reinforced by determining the efficacy of other histamine(H1) antagonists as inhibitors of PAF-induced airway hyperreactivity. When compounds were administered intravenously, at a dosage (1 mg/kg) which fully abolished responses to intravenous histamine, the observed rank order for inhibition of PAF-induced hyperreactivity was: ketotifen greater than cetirizine greater than acrivastine greater than KB-2413 greater than oxatomide greater than azelastine greater than terfenadine = astemizole = clemastine = mepyramine = loratadine = saline. Terfenadine may lack inhibitory activity because of a capacity to induce airway hyperreactivity in the guinea-pig. It can be concluded that inhibition of the development of airway hyperreactivity is not a characteristic of histamine(H1) antagonists.

摘要

酮替芬可抑制暴露于血小板活化因子(PAF)、(±)异丙肾上腺素、免疫复合物或内毒素的豚鼠气道高反应性的发展。酮替芬不是竞争性组胺(H1)拮抗剂,因此不能得出组胺必然参与这些形式的气道高反应性的发生或表达的结论。通过测定其他组胺(H1)拮抗剂作为PAF诱导的气道高反应性抑制剂的效力,这一结论得到了加强。当以完全消除对静脉注射组胺反应的剂量(1mg/kg)静脉注射化合物时,观察到的抑制PAF诱导的高反应性的顺序为:酮替芬>西替利嗪>阿伐斯汀>KB-2413>奥沙米特>氮卓斯汀>特非那定 = 阿司咪唑 = 氯马斯汀 = 美吡拉敏 = 氯雷他定 = 生理盐水。特非那定可能由于具有诱导豚鼠气道高反应性的能力而缺乏抑制活性。可以得出结论,抑制气道高反应性的发展不是组胺(H1)拮抗剂的特征。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验